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ABSTRACT
Owing to the rapid progress in stem cell research (SCR) and regenerative medicine (RM), society’s
expectation and interest in these ﬁelds are increasing. For effective communication on issues con-
cerning SCR and RM, surveys for understanding the interests of stakeholders is essential. For this pur-
pose, we conducted a large-scale survey with 2,160 public responses and 1,115 responses from the
member of the Japanese Society for Regenerative Medicine. Results showed that the public is more
interested in the post-realization aspects of RM, such as cost of care, countermeasures for risks and
accidents, and clariﬁcation of responsibility and liability, than in the scientiﬁc aspects; the latter is of
greater interest only to scientists. Our data indicate that an increased awareness about RM-
associated social responsibility and regulatory framework is required among scientists, such as those
regarding its beneﬁts, potential accidents, abuse, and other social consequences. Awareness regard-
ing the importance of communication and education for scientists are critical to bridge the gaps in
the interests of the public and scientists. STEM CELLS TRANSLATIONAL MEDICINE 2018;7:251–257
SIGNIFICANCE STATEMENT
This study analyzed the differences between the knowledge that scientists prefer to share with
the public and those that actually interest the public. Generally speaking, the public is inter-
ested in knowing about the outcome of using regenerative medicine and how to manage the
problems that may occur after using such medicine. Further communication between scientists
and the public is required to create a common future vision.
INTRODUCTION
Successful generation of human induced pluripo-
tent stem cells (iPSCs) in Japan and the U.S. in
2007 gained signiﬁcant public attention world-
wide. Subsequently, news regarding research on
iPSCs and iPSC-derived products captured the
media limelight. Interest in iPSCs has inﬂuenced
both the public and scientists. Terms such as iPSCs
and regenerative medicine (RM) are used com-
monly, and public support for stem cell research
(SCR) and RM has increased [1].
The Japanese Ministry of Education, Sports,
Culture, Science, and Technology (MEXT) has
invested 10 billion yens for promoting research
and development of iPSCs over a 5-year period
since March 2008 [2]. Following the initial genera-
tion of iPSCs, SCR, and RM using pluripotent stem
cells (PSCs) have become central topics in Japa-
nese science policy. The Japanese authorities have
recently changed SCR and RM-related regulations.
The Act on the Promotion of Regenerative Medi-
cine (APRM) and the Act on the Safety of Regener-
ative Medicine (ASRM) have been implemented,
and the Pharmaceutical and Medical Device Act
(PMDA) has been revised [3]. These three acts are
collectively known as the “Regenerative Medicine
Three Acts (RMTAs).”
These policies, which primarily address the
risky nature of “ﬁrst-in-human,” were imple-
mented after several clinical accidents with legal
actions, such as that involving the administration
of stem cells without safety approval [4]. Issues
related to iPSC and RM-related hype have addi-
tionally been highlighted.
Under the recently revised guidelines, the
International Society for Stem Cell Research
(ISSCR) recommends that the SCR community
should promote “accurate, balanced, and respon-
sive public representations” of SCR [5].
Clinical trials of RM using PSCs have recently
been initiated in Japan. Dr. Masayo Takahashi’s
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group is undertaking the ﬁrst-in-man clinical trials of iPSC-derived
retinal pigment cells in patients with age-related macular degener-
ation [6] under careful monitoring. However, the actual picture of
a PSC-driven RM society is still unknown. Under such circumstan-
ces, imagining a future society with RM is challenging. An impor-
tant question is who should tackle this difﬁcult but creative work?
Since scientiﬁcally accurate and adequate information is not
always available, for example, regarding self-entitled “safe stem
cell therapy clinics,” Lau et al. (2008) indicated that patients avail-
ing such treatments are at risk [7]. As a part of the current efforts
for solving these issues in Japan, the Ministry of Health, Labor, and
Welfare (MHLW) has established certiﬁed committees. Any RM-
based clinical plan has to pass through the review process of this
committee and mandatory notiﬁcation has to be submitted [3].
An overview of the ethical, legal, and social implications (ELSIs)
of SCR and RM shows that the public concerns remain unan-
swered. For example, Inoue et al. (2016) showed that the public
expressed reservations regarding human-animal chimera studies
[8]. Although over 70% respondents have positive and supportive
attitude toward promotion of RM-related research, approximately
half of the respondents had negative attitude toward generation
of human-animal chimera. Another research showed that the rela-
tionship between education, religion, and medical history of the
respondents and their families and attitude toward use of human-
animal chimera is complex and difﬁcult to interpret [9].
In the context of the rapid progress and signiﬁcant impact of
SCR and RM, communication regarding advanced science and tech-
nology between the scientiﬁc community and the society has
become a critical science policy issue worldwide [10–14]. An impor-
tant lesson regarding communication can be learnt from controver-
sies on genetically modiﬁed organisms (GMOs). For example, the
U.K. government attempted to coordinate and manage the discus-
sion and communication regarding the social aspects of GMOs in
2000. They conducted a variety of communication-oriented activ-
ities such as group interviews, consensus, conference, and public
consultations, to understand public interest in GMOs and improve
the mutual communication between the scientiﬁc community and
the public. However, these trials highlighted that the discussions
turned into controversies and conﬂicts, which was the limitation of
such communication activities. Although several key questions on
GMOs have been shared between the scientiﬁc community and
the public, the most important lesson learnt was that these activ-
ities should have been conducted earlier. In other words, upstream
and early stage communication is essential for effective communi-
cation on advanced science and technology [15–19].
This lesson can be adapted in the Japanese context for SCR
and RM. Owing to the increased anticipation regarding RM, com-
munication between the scientiﬁc community and society on SCR
and RM has become a critical issue. Japanese science policies
have encouraged communication between the scientiﬁc commu-
nity and the society in general. The Second Science and Technol-
ogy Basic Plan in 2001 indicated the importance of scientists’
outreach activities to society [20]. In addition, The Third Science
and Technology Basic Plan in 2006 emphasized the need for
mutual communication between scientists and the public [21].
According to this trend, activities concerning science communica-
tion, such as science cafe or open laboratories, have increased
since 2000 [22, 23]. More currently, The Fourth Science and
Technology Basic Plan in 2011 emphasized the importance of
risk communication [24]. The latest basic plan in 2016—The
Fifth Science and Technology Basic Plan—emphasized mutual
communication between scientists and the public with the key
word “communication for co-creation,” particularly in advanced
ﬁelds such as SCR and RM [25]. In summary, discussions concern-
ing SCR and RM, including topics of ELSIs, between the scientiﬁc
community and the society are urged to ensure the accountabil-
ity of scientists to society [25]. For this purpose, previous studies
indicated systemic measures for promoting communication skills
of scientists, such as implementation of evaluation systems, infra-
structure, and so on [26, 27]. The same structural issues were
suggested for SCR and RM [28]. In addition, to generate a pro-
communication infrastructure for SCR and RM, it is essential to
understand the nature of the topics that interest the public and
the factors they consider important for the acceptance of RM for
effective communication. However, the current lack of knowledge
regarding public and scientists’ attitude toward communication
on RM is a serious challenge. Therefore, we conducted a survey
to examine the attitudes of scientists and the public toward SCR
and RM. This work reports a survey in the Japanese context, the
ﬁndings of which would foster future communication between
scientists and the public regarding SCR and RM worldwide.
MATERIALS AND METHODS
From October 2015 to March 2016, we circulated a survey
questionnaire among members of the Japanese Society of Regen-
erative Medicine (JSRM), who consisted of investigators of stem
cell and biomaterials, medical doctors, policymakers, journalists,
and so on. We collected 1,115 valid responses, representing a
response rate of 22.1%. The public respondents were contacted
through a research and monitoring company (the Japan Research
Center), and 2,160 valid responses were collected.
We designed multiple choice questions to facilitate compari-
son between the answers provided by JSRM members and the
public (Table 1). Questions were designed based on previous stud-
ies of public attitude toward nuclear energy [29, 30]. The key
questions were “What do you want to know? (What do you want
to convey?)” and “What factors are important for your acceptance
of RM?” Table 1 shows the rough sketch of our questionnaire.
RESULTS
Gap in Imagination Between JSRM Members and the
Public
Approximately 80% of the respondents were supportive of RM and
60.7% expressed that they would (like to) donate their cells or blood.
In this context, the differences in imagination about RM
between JSRM members and the public should be resolved for
developing effective communication. Figure 1 shows the responses
to “How long it will take to achieve RM with iPS cells?” “Within 10
years” was the most answered item (46.2%). At the same time,
10.0% answered “within 20 years,” 30.6% answered “within sev-
eral years.” In contrast, only 1.5% answered “one year.”
Overall, the expectation of the public is slightly shorter than
those of the JSRM members. Despite the differences in opinion
between JSRM members and the public, the current result shows
that the majority of the public concur with the JSRM members,
compared with the results of a previous study [31]. However, the
differences in the imagination of JSRM members and the public
are noteworthy.
The differences in expectations from RM within 10 years
between JSRM members and the public emphasize this division
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(Fig. 2). The most numbered answer was “reduce pains and bur-
dens” (public: 45.0%, JSRM members: 50.5%). However, the ten-
dencies varied with other answers; 25.7% of the public and 15.3%
of the JSRM members answered “replacement of sick organs,”
whereas 18.5% of the public and 7.5% of the JSRM members
answered “life-span extension.” Furthermore, 25.9% JSRM mem-
bers and 9.0% of the public answered “not much change.”
These results indicate that the expectations triggered by the
keyword “regenerative medicine” differed considerably between
the public and the scientiﬁc community. This also suggests that tri-
als are necessary to reduce these gaps.
Gaps in Focus Between the Scientific Community and
the Public
Over 70% of the public expressed that they wished to know more
about “risk” and “anticipated new medical care.” These topics
were also of high interest to JSRM members (53.2% and 78.9%).
Additionally, approximately 60% of the public were interested
about the “cost of care.” “Measures for safety” and “responses to
medical accidents” were also highly marked (52.6% and 47.3%).
Interestingly, signiﬁcant differences in responses related to the
“mechanism of RM,” “medical application and clinical testing,”
and “industrial possibilities” were observed between the two
groups (p< .01)., with JSRM members more interested on scien-
tiﬁc content than the public (Fig. 3).
Differences were noted regarding factors considered impor-
tant for the acceptance of SCR and RM (p< .01) (Fig. 4). JSRM
members emphasized the importance of scientiﬁc validation
(55.0%) and necessity of research (36.3%). The public, however,
regarded the effectiveness of regulation (50.5%), probabilities of
potential risks and accidents (33.5%), and clariﬁcation of responsi-
bility and liability (32.2%) as more important factors. In addition,
controllability represented a common important point between
the two groups (public: 55.7%, JSRMmembers: 57.6%).
In addition, we asked “What is the decisive factor for consider-
ing donation of your biomaterials to research?” Although JSRM
members regard “protection of privacy” or “pain” as important
factors, the public consider “advice from a credible medical
doctor,” “achievement in future,” and “sample end-users?” as
important deciding factors for donation (Fig. 5).
In summary, we observed that JSRM members focused on sci-
entiﬁc content and validation, considering the current lack of clini-
cal trials on RM. However, the public’s primary interest in SCR and
RM was related to the consequences of the potential success of
RM, such as the cost of new drugs and the treatment available in
case of accidents. The public was also interested in issues regard-
ing post-accident responsibility and responsiveness, which indi-
cated a pragmatic attitude. These differences between the public
and JSRM members should be analyzed since the public expects
RM to be a reality in the near future (see also Figs. 1, 2).
In addition, the public regarded “trust” as an important factor
for donation (Fig. 5).
Knowledge of Regulatory Frameworks and Social
Aspects of RM Among JSRM Members
Figure 6 shows the responses of JSRM members to the following
questions: “Are you aware of the Regenerative Medicine Three
Acts?” and “Do you know of any cases of fatal clinical accidents
Table 1. Questions asked in this survey




Opinion for promotion of RM research
Expected time of achievement of RM
Expected contents of RM after 10 years
Expected time of achievement of RM
Expected contents of RM after 10 years
Interesting topics on RM What do you want to know?
What factors are important for
your acceptance of RM?
What factors are important for donating
your biomaterial?
What do you want to convey?
What factors are important for
your acceptance of RM?
What factors are important for people
to consider donation of their biomaterial?
Recognition of social
events on RM
About the RM three acts
About the clinical case of RM
About the RM three acts
About the clinical case of RM
Demography Age, gender, education, income, religion, expertise, and so on
Gaps in Focus between the Public and Scientists regarding factors considered important for the acceptance of stem cell research and regenerative
medicine (RM) (p< .01).
Abbreviations: iPSCs, induced pluripotent stem cells; RM, regenerative medicine.
Figure 1. Responses to “How long will it take to achieve regenera-
tive medicine with iPS cells?” Abbreviation: JSRM, Japanese Society
of Regenerative Medicine.
Figure 2. Responses to “Which is a suitable expectation of the pro-
gress of regenerative medicine within 10 years?” Abbreviation:
JSRM, Japanese Society of Regenerative Medicine.
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related to the administration of stem cell therapies?”; 72.0% of
JSRM members answered that they had a knowledge outline on
these topics or could explain the Regenerative Medicine Three
Acts. However, our results show that a fourth of the surveyed
JSRM members lacked basic knowledge of the regulatory frame-
work and policies of their funding source. JSRM members in
Figure 3. Differences in the response between JSRM members and the public to “What do you want to know?” (for the public) and “What
do you want to convey?” (for JSRM members) “Please choose ﬁve factors” and “Don’t know or other” answers were omitted because of the
low ratio. Chi-square test was conducted; **, p< .01. Abbreviation: RM, regenerative medicine.
Figure 4. Differences in the response between Japanese Society of Regenerative Medicine members and the public to “What factors are
important for your acceptance of regenerative medicine? Please choose three factors.” “Don’t know or other” answers were omitted because
of the low ratio. Chi-square test was conducted; **, p< .01. Abbreviation: RM, regenerative medicine.
Figure 5. Differences in response between Japanese Society of Regenerative Medicine members and the public to “What is the decisive fac-
tor for considering donation of your biomaterials to research? Please choose three factors.” “Don’t know or other” answers were omitted
because of the low ratio. Chi-square test was conducted; **, p< .01.
254 Differing Views on Stem Cell Research
Oc 2018 The Authors Stem Cells Translational Medicine published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
clinical ﬁelds understood regulatory aspects better than those in
basic research (p< .01).
At the same time, <60% of the respondents were aware of
the fatal clinical accident arising from administration of stem cells
in 2010 [32]. Interestingly, no signiﬁcant difference in terms of this
knowledge was observed between basic and clinical scientists.
To address controversies related to the application of RM in
society, it is necessary to educate the scientiﬁc community
regarding the social aspects and regulatory frameworks related to
RM.
DISCUSSION
At the international level, Kamenova and Cauﬁeld analyzed news
articles on clinical trials involving transplantation of embryonic
stem cell-derived neural precursor cells for treatment of spinal
damage and observed the emergence of an overall optimistic
tone [33]. Society’s expectation for RM has increased, and RM
clinics are now common worldwide; however, the expectations
are not based on accurate scientiﬁc understanding. The deﬁcit in
basic quantitative knowledge due to the lack of scientiﬁc informa-
tion transmission from the scientiﬁc community has serious policy
implications. Regulatory authorities may be hesitant to enforce
actions without a clear understanding of RM [34, 35]. Further-
more, a considerable body of news on SCR and RM was broadcast
in the Japanese mass media, following the initial implementation
of human iPSCs. However, Japanese mass media tended to broad-
cast a national promotion of SCR and RM, rather than exploring
ELSIs [36].
Considering the above situation, development of more and
effective means of communication between academic societies
and the public are urgently required. The present survey showed
that the public is more interested in the post-realization aspects
of RM, such as cost of care, countermeasures for risks and
accidents, and clariﬁcation of responsibility and liability, than in
the scientiﬁc aspects, whereas the latter is of greater interest only
to JSRM members (Figs. 3, 4). Consequently, patients and civilians
are exposed to unnecessary risk. In addition, recognition of the
social aspects of RM among JSRM members was low (Fig. 2). This
gap of communication, if left unattended, might negatively affect
everyone. Simultaneously, the “trust” of the public on healthcare
providers/developers of RM should be considered while develop-
ing strategies to bridge these gaps (Fig. 5). In summary, communi-
cation trials concerning RM should be conducted, considering the
pragmatic interests of the public. While scientiﬁc facts should
form the basis of dialogues between the public and JSRM mem-
bers, there is a need for increasing the awareness on the wider
aspects of RM, such as an understanding of factors that may arise
after the implementation of RM.
The above-mentioned point can be related to the current dis-
cussion on “Responsible Research and Innovation (RRI)” in Euro-
pean science policy. Recently, the concept of RRI was discussed
and applied to science policy, particularly in the European frame-
work Horizon 2020 [37]. This concept recommends greater com-
munication, engagement, and inclusion of various stakeholders in
science and technology innovation. Therefore, RRI has been
deﬁned as “responsible innovation means taking care of the
future through collective stewardship of science and innovation in
the present” [38]. The societal impact of scientiﬁc research, espe-
cially those related to SCR and RM, and the ways in which visions
for the future may be shared with society are the focus of such
policies [39].
As an example of RRI for RM, a new compensation system for
RM therapy was launched in November 2016 by the JSRM and
the Mitsui Sumitomo Insurance [40]. Donors and recipients in clin-
ical studies, as deﬁned by RMTAs, were covered by the previous
compensation system. However, in terms of compensation for
RM-based therapies, only donors have been targeted. The new
Figure 6. Differences in response between JSRM members and the public about the following questions. (A): Response of Japanese Society
of Regenerative Medicine (JSRM) members to “Are you aware of the Regenerative Medicine Three Acts?” (B): Responses of JSRM members
to “Do you know any cases of fatal clinical accidents related to the administration of stem cell therapies?”
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compensation system aims to provide protection to the recipients.
In addition, the JSRM has initiated communication efforts, includ-
ing questionnaires, surveys, and implementation of lecture meet-
ings and science cafes with funding from the “risk communication
model project” by the MEXT. Furthermore, JSRM has initiated
“the Regenerative Medicine National Consortium,” which is sup-
ported by AMED, for solving various issues related to the conduct
and supervision of objective research and for the promotion of all-
Japan RM research. As part of this project, we plan to establish a
consultation window for society on matters related to RM [41].
As described above, this change has been implemented partly
in response to public interest, and should be continued apace.
However, increased recognition of this new scheme within the sci-
entiﬁc community is necessary for RRI of RM, although it may be
challenging to achieve harmonization between society’s interests
and RM by maximizing the effect of this new scheme.
CONCLUSION
As society’s interest in RM is increasing, further efforts are
required to bridge the difference in knowledge. In contrast, JSRM
members’ lack of understanding of the public’s social interests
regarding RM would generate issues such as communication bias
and misunderstanding of RM. Notably, a proportion of the JSRM
members’ lacked knowledge regarding the social and regulatory
aspects of RM. In Japan, governmental investigations have been
conducted for non-compliance with RM laws, which highlights the
importance of RM regulation-related education. The JSRM has
established a system that provides certiﬁcation qualiﬁcations to
enhance education for academic members and thereby contribute
to quality medical treatment and patient protection [18].
Our data indicate that an increased awareness about RM-
associated social responsibility and regulatory framework is
required among scientists, such as those regarding its beneﬁts,
potential accidents, abuse, and other social consequences.
Accordingly, training programs focusing on RM science policy and
regulatory frameworks for scientists are essential.
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